Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $116.45, for a total transaction of $617,185.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Monday, October 30th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The shares were sold at an average price of $101.12, for a total value of $535,936.00.
  • On Friday, September 29th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The shares were sold at an average price of $108.86, for a total value of $576,958.00.

Shares of Edwards Lifesciences Corporation (EW) traded up $0.83 during trading hours on Thursday, reaching $117.20. The company’s stock had a trading volume of 2,192,288 shares, compared to its average volume of 1,636,207. The company has a market cap of $23,957.49, a PE ratio of 31.36, a P/E/G ratio of 2.03 and a beta of 0.46. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The firm had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.68 earnings per share. sell-side analysts expect that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year.

A number of research analysts have issued reports on EW shares. Canaccord Genuity reissued a “buy” rating and set a $135.00 price objective (down from $155.00) on shares of Edwards Lifesciences in a report on Wednesday, October 25th. BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences in a report on Friday, September 1st. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a report on Monday, August 28th. SunTrust Banks set a $124.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Morgan Stanley cut their price target on Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a report on Thursday, October 26th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $125.27.

Large investors have recently made changes to their positions in the business. ETF Managers Group LLC bought a new stake in Edwards Lifesciences during the 2nd quarter worth about $112,000. Shine Investment Advisory Services Inc. bought a new stake in Edwards Lifesciences during the 2nd quarter worth about $126,000. MPS Loria Financial Planners LLC bought a new stake in Edwards Lifesciences during the 2nd quarter worth about $140,000. Dupont Capital Management Corp bought a new stake in Edwards Lifesciences during the 3rd quarter worth about $142,000. Finally, Captrust Financial Advisors bought a new stake in Edwards Lifesciences during the 2nd quarter worth about $149,000. 81.55% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/30/edwards-lifesciences-corporation-ew-vp-sells-617185-00-in-stock.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.